Danaher Corporation vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) — how do they compare? Danaher Corporation trades at $217 (market cap $153.60B), while Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) trades at $7.78 (market cap $8.28B). The key difference: Danaher Corporation is far larger — about 18.6× Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)'s market cap, and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) pays the higher dividend (4.85%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) for 0 Days on average.
| DHR | UGP | |
|---|---|---|
Market Cap | $153.60B | $8.28B |
Volume | 3,974,063 | 3,583,950 |
Sector | Health | Energy |
52-Week High | $242.05 | $7.79 |
52-Week Low | $161.91 | $3.63 |
Typical Hold Time | 69 Days | 0 Days |
Enterprise Value | $175.81B | $10.35B |
Dividend Yield | 0.73% | 4.85% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Ultrapar is a Brazilian company with fuel distribution, liquefied petroleum gas, and chemical businesses. Its consumer-facing operations include fuel and gas distribution brands.
Read more on UGP →